Skip to content

Nasal air suction in the treatment of acute migraine headache

Effectiveness of para nasalsinus air suction in the treatment of acute migraine headache - A randomized, double-blind, placebo-controlled Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
SLCTR
Registry ID
SLCTR/2017/018
Enrollment
Unknown
Registered
2017-06-29
Start date
2016-07-04
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Interventions

The study will be carried out among school children in the Kandy District. Participant allocation will be through stratified block randomization. A total of 12 schools will be selected using simple

Sponsors

Dr. S.M. Rathnasiri Bandara
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male and female school children 2. Age 16-19 years 3. Diagnosed with migraine according to the IHS-criteria ICHD-II 1.1: Migraine without aura [G43.0] 1.2: Migraine with aura [G43.1] 4. Complaint of a single migraine headache of moderate or severe intensity

Exclusion criteria

Exclusion criteria: 1. History of cranial lesion or tumor 2. Recent nasal or sinus infective illness, trauma and runny nose 3. Smoking 4. Known to abuse alcohol or drugs 5. Females on hormonal therapy for any condition or illness 6. Diagnosed psychiatric illness 7. Any other acute or chronic illness 8. Participants on non-medical/non-nutritional treatment for migraine prevention such as acupuncture or psychotherapy. 9. Participants on current medical treatment for acute migraine or migraine prophylaxis 10. Non-provision of informed consent and/or having lack of understanding of the information regarding the study

Design outcomes

Primary

MeasureTime frame
Headache relief (defined as reduction of headache pain intensity from severe or moderate migraine headache to mild or none) at 60 seconds post-application of the device - using a 10 point pain scale and a 4 point Glaxo visual analogue scale. [At 60 seconds post-application of the device and at the completion of 1, 2, 4, 6, 12 and 24 hours post–application of the device] Change in severity of suborbital tenderness/ scalp tenderness due to migraine headache - - using a 10 point pain scale and a 4 point Glaxo visual analogue scale. [At 60 seconds post-application of the device and at the completion of 1, 2, 4, 6, 12 and 24 hours post–application of the device]

Secondary

MeasureTime frame
None [None]

Contacts

Public ContactDr. S.M. Rathnasiri Bandara

Medical Officer

rathnasirib68@gmail.comTel: 0823233341

Outcome results

None listed

Source: SLCTR (via WHO ICTRP) · Data processed: Aug 9, 2026